View Older Stories View More Recent Stories

Dec 21, 2020 09:17AM Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine
Dec 14, 2020 06:16AM Pfizer (PFE), BioNTech SE (BNTX) Highlight Data on Neutralizing Antibody & T-Cell Responses from Phase 1/2 Trial with BNT162b2 Conducted in Germany
Dec 14, 2020 06:00AM Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2
Dec 12, 2020 04:58PM U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older
Dec 12, 2020 09:29AM Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Receives FDA Emergency Use Authorization
Dec 11, 2020 11:15PM Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
Dec 11, 2020 11:12PM Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
Dec 10, 2020 06:51PM Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
Dec 10, 2020 06:50PM Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
Dec 10, 2020 06:50PM Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
Dec 10, 2020 10:46AM Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Dec 10, 2020 10:46AM Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Dec 10, 2020 10:21AM Pfizer (PFE) , BioNTech (BNTX) Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in NEJM
Dec 10, 2020 10:21AM Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Dec 9, 2020 11:06AM Pfizer (PFE) and BioNTech (BNTX) Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19
Dec 9, 2020 11:04AM Pfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19
Dec 9, 2020 11:03AM Pfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19
Dec 2, 2020 05:53AM Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Approved in U.K.
Dec 2, 2020 02:05AM Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
Dec 2, 2020 02:05AM Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
Dec 2, 2020 02:05AM Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
Dec 1, 2020 06:08AM Pfizer (PFE), BioNTech (BNTX) Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
Dec 1, 2020 05:00AM Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
Dec 1, 2020 05:00AM Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
Nov 20, 2020 05:17PM Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate
Nov 20, 2020 06:45AM Pfizer (PFE), BioNTech (BNTX) to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
Nov 20, 2020 06:45AM Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
Nov 20, 2020 06:45AM Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
Nov 20, 2020 06:45AM Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
Nov 18, 2020 07:14AM Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
Nov 18, 2020 07:13AM Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
Nov 18, 2020 07:00AM Pfizer (PFE), BioNTech (BNTX) Confirm Phase 3 Study of COVID-19 Vaccine Candidate Shows 95% Efficacy
Nov 18, 2020 06:59AM Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
Nov 16, 2020 11:21AM Exclusive: EU eyes COVID vaccine deal with Moderna at less than $25 per dose, says source
Nov 11, 2020 06:16AM Pfizer (PFE) and BioNTech (BNTX) Confirm Agreement to Supply EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2
Nov 11, 2020 06:16AM Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
Nov 11, 2020 06:15AM Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
Nov 11, 2020 06:15AM Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2
Nov 9, 2020 11:14AM Retail trading hits snags as vaccine news sparks stock scramble
Nov 9, 2020 06:45AM Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Shows Over 90% Efficacy in Phase 3 Study
Nov 9, 2020 06:45AM Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Nov 9, 2020 06:45AM  Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Nov 9, 2020 06:45AM Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Oct 6, 2020 06:06AM BioNTech (BNTX) and Pfizer (PFE) Initiate Rolling Submission to EMA for SARS-CoV-2 Vaccine Candidate BNT162b2
Oct 6, 2020 05:01AM BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
Oct 6, 2020 05:01AM BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
Sep 15, 2020 01:45PM Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
Sep 14, 2020 06:17AM Pfizer (PFE), BioNTech SE (BNTX) Announce Submission to FDA to Expand Enrollment of Phase Pivotal COVID-19 Trial up to Approx. 44K Participants
Sep 12, 2020 11:17AM Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
Sep 12, 2020 11:17AM Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
View More Recent Stories View Older Stories